8-K: Intensity Therapeutics Reports Q3 2025 Results, Extends Runway

Intensity Therapeutics announced its third quarter 2025 financial results, provided a corporate update on its clinical trials, and extended its cash runway into Q1 2027.

Summary

• Reported third quarter 2025 financial results.
• Paused new patient enrollment in the INVINCIBLE-4 Study in September 2025 to revise the dosing regimen for the INT230-6 treatment cohort due to localized skin irritation.
• Expects to file a protocol amendment for the INVINCIBLE-4 Study in the first quarter of 2026 and reinitiate patient enrollment in the same quarter, targeting completion by the end of 2026.
• Paused new site activations and patient enrollments in the INVINCIBLE-3 Study in March 2025 due to funding constraints, with 21 patients enrolled; continues to treat existing patients.
• Published the IT-01 Study manuscript in eBioMedicine on October 29, 2025, featuring a 75% disease control rate and median overall survival of 11.9 months in heavily pretreated advanced solid tumor patients.
• Raised $13.6 million in gross proceeds since the beginning of the third quarter of 2025, including $7.5 million in Q3, $2.1 million in October via ATM, and $4.0 million in October via a registered direct offering.
• Extended cash runway until the end of the first quarter of 2027.
• Net loss for the three months ended September 30, 2025, was $2.7 million, compared to a net loss of $3.5 million for the same period in 2024.
• Cash and cash equivalents totaled $7.1 million as of September 30, 2025.

Sentiment

Score: 7

Explanation: The extension of the cash runway, successful capital raises including a new institutional investor, and the positive peer-reviewed publication of IT-01 data are strong positives. However, the pauses in both ongoing clinical trials (INVINCIBLE-3 due to funding, INVINCIBLE-4 due to dosing regimen revision) temper the overall sentiment, indicating ongoing operational challenges despite financial improvements.

Positives

• Cash runway extended until the end of the first quarter of 2027 due to recent capital raises, significantly improving financial stability.
• Successfully raised $13.6 million in gross proceeds since Q3 2025, including a significant $4.0 million registered direct offering that brought in a new long-term institutional investor.
• The IT-01 Study manuscript was published in eBioMedicine, a Lancet Discovery Science journal, providing peer-reviewed validation of INT230-6's potential.
• IT-01 study results showed a 75% disease control rate and median overall survival of 11.9 months in heavily pretreated patients with advanced solid tumors, comparing favorably to historical phase 1/2 studies (4-7 months mOS).
• Exploratory analysis in IT-01 demonstrated improved survival (mOS 18.7 months vs 3.1 months) and an 83.3% disease control rate when greater than 40% of total tumor burden was treated.
• Approximately 20% of patients in the >40% TTB group experienced abscopal effects, where uninjected tumors shrank, indicating systemic immune activation.
• No dose-limiting toxicities, Grade 4 or 5 treatment-related adverse events were reported among 64 monotherapy patients in the IT-01 study.
• Pharmacokinetic results from IT-01 showed that greater than 95% of the active cytotoxic agents remained in the injected tumors, contributing to a favorable safety profile.
• Net loss decreased to $2.7 million in Q3 2025 from $3.5 million in Q3 2024.

Negatives

• New patient enrollment in the INVINCIBLE-4 Study was paused in September 2025 due to some patients experiencing localized skin irritation near the tumor site, requiring a protocol amendment.
• New site activations and patient enrollments in the INVINCIBLE-3 Study were paused in March 2025 due to funding constraints, and the restart is contingent on obtaining sufficient funding.
• Research and development expenses decreased by $0.4 million primarily due to lower INVINCIBLE-3 Study costs, reflecting the ongoing pause in that trial.

Risks

• Actual results may differ materially from forward-looking statements due to various factors.
• The initiation, timing, progress, and results of future preclinical studies and clinical trials and research and development programs are uncertain.
• The Company will need to raise additional funding before it can expect to generate any revenues from product sales.
• There is a risk that product candidates appearing promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials.
• The Company's ability to maintain and establish collaborations or obtain additional funding is crucial for its operations.
• There is a potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing, which could lead to delisting.

Future Outlook

The Company expects to file a protocol amendment for the INVINCIBLE-4 Study in the first quarter of 2026 to revise the dosing regimen and reinitiate patient enrollment in the same quarter, targeting completion by the end of 2026. The INVINCIBLE-3 Study remains paused but will restart site activations and patient enrollment once sufficient funding is obtained. With recent capital raises, the cash runway is extended until the end of the first quarter of 2027.

Management Comments

• "In the past four months, we were able to substantially improve our balance sheet with multiple fundraising transactions."
• "The October 2025 registered direct offering was significant, as this brought in a new long-term fundamental, healthcare-savvy investor."
• "The new capital raised in 2025 enables us to execute on our business strategy until the end of the first quarter of 2027 without any additional funds."
• "Our peer-reviewed paper published in the Lancet Discovery Groups journal, eBioMedicine, provides another level of validation of the potential of our lead drug INT230-6, injected directly into tumors, to treat multiple types of cancer in both the metastatic and local disease settings."
• "We believe this is the first peer-review publication of a local therapy alone to report disease control rate, the potential for an overall survival benefit and a 20% patient abscopal rate in metastatic disease."
• "Working with our collaboration partners at the Swiss Cancer Institute, we analyzed the data from the patients in the Phase 2 randomized controlled INVINCIBLE-4 study, and have identified a path forward to restarting the study, which is expected to be in the first quarter of 2026."
• "The endpoint will remain pathological complete response, which is accepted by FDA for accelerated approval."

Industry Context

Intensity Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on novel intratumoral cancer therapies. The publication of positive Phase 1/2 data for INT230-6 in a prestigious journal like eBioMedicine provides significant validation, potentially differentiating it from other local therapies by demonstrating systemic effects (abscopal effects) and favorable survival rates in heavily pretreated patients. The challenges with funding and trial pauses are common in early to late-stage biotech, highlighting the need for continuous capital raises to advance clinical programs. The focus on triple-negative breast cancer and soft tissue sarcoma addresses areas with significant unmet medical needs.

Comparison to Industry Standards

• The IT-01 study's median overall survival (mOS) of 11.9 months in heavily pretreated advanced solid tumor patients compares favorably to historical phase 1/2 studies that typically report an mOS of 4 to 7 months for similar patient populations.
• The 20% abscopal rate observed in the >40% TTB group for uninjected tumors shrinking is a notable finding for a local therapy, suggesting systemic immune activation, which is a key goal for many immuno-oncology treatments.
• The disease control rate of 75% in the IT-01 study is strong for a monotherapy in heavily pretreated patients across over 20 different cancer types.
• The INVINCIBLE-4 study's primary endpoint of pathological complete response (pCR) is an accepted endpoint by the FDA for accelerated approval in breast cancer, aligning with regulatory pathways for novel therapies.

Stakeholder Impact

• Shareholders: Positive impact from extended cash runway and validation of INT230-6 data, but potential concern from trial pauses and the need for future funding for INVINCIBLE-3.
• Patients: Continued treatment for enrolled INVINCIBLE-3 patients, but delays for new patients in both INVINCIBLE-3 and INVINCIBLE-4 studies. Potential benefit from revised dosing in INVINCIBLE-4 for safety.
• Employees: Increased stability due to extended cash runway.
• Contract Research Organizations (CROs): Continued engagement for ongoing INVINCIBLE-3 patients, but reduced activity for new enrollments/site activations.

Next Steps

• File a protocol amendment for the INVINCIBLE-4 Study in the first quarter of 2026.
• Reinitiate patient enrollment for the INVINCIBLE-4 Study in the first quarter of 2026.
• Target completion of INVINCIBLE-4 enrollment by the end of 2026.
• Restart site activations and patient enrollment in the INVINCIBLE-3 Study once sufficient funding is obtained.
• Continue to treat patients already enrolled in the INVINCIBLE-3 Study.

Key Dates

Recommendation

While the company has significantly improved its financial position by extending its cash runway into Q1 2027 and securing a new institutional investor, and the peer-reviewed publication of IT-01 data is a strong validation, the pauses in both key clinical trials (INVINCIBLE-3 due to funding, INVINCIBLE-4 for dosing revision) introduce uncertainty. The positive data from IT-01 is encouraging, but the path to market still faces significant hurdles and potential delays. Investors should hold to monitor the successful reinitiation of INVINCIBLE-4 and the securing of funding for INVINCIBLE-3 before considering further investment.

Keywords

Intensity Therapeutics, INTS, Biotechnology, Cancer Therapy, INT230-6, Oncology, Clinical Trials, Triple-Negative Breast Cancer, Soft Tissue Sarcoma, Intratumoral Injection, DfuseRx, Financial Results, Cash Runway, SEC Filing, Q3 2025, INVINCIBLE-4, INVINCIBLE-3, IT-01